As a result, other trials involving onartuzumab plus erlotininb, such as a phase 2 study evaluating the efficacy of first-line onartuzumab plus erlotininb in MET-positive and EGFRm NSCLC, were also terminated [57]. Here, MET is linked to non-small cell lung carcinoma.